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Abstract
Background:Renaldysfunctionisanestablishedpredictorofall-causemortalityinintensivecareunits.Thisstudyanalyzedthe
outcomes of coronary care unit (CCU) patients and evaluated several biomarkers of acute kidney injury (AKI), including
neutrophilgelatinase-associatedlipocalin(NGAL),interleukin-18(IL-18)andcystatinC(CysC)onthefirstdayofCCUadmission.
Methodology/Principal Findings: Serum and urinary samples collected from 150 patients in the coronary care unit of a
tertiary care university hospital between September 2009 and August 2010 were tested for NGAL, IL-18 and CysC.
Prospective demographic, clinical and laboratory data were evaluated as predictors of survival in this patient group. The
most common cause of CCU admission was acute myocardial infarction (80%). According to Acute Kidney Injury Network
criteria, 28.7% (43/150) of CCU patients had AKI of varying severity. Cumulative survival rates at 6-month follow-up following
hospital discharge differed significantly (p,0.05) between patients with AKI versus those without AKI. For predicting AKI,
serum CysC displayed an excellent areas under the receiver operating characteristic curve (AUROC) (0.89560.031, p,0.001).
The overall 180-day survival rate was 88.7% (133/150). Multiple Cox logistic regression hazard analysis revealed that urinary
NGAL, serum IL-18, Acute Physiology, Age and Chronic Health Evaluation II (APACHE II) and sodium on CCU admission day
one were independent risk factors for 6-month mortality. In terms of 6-month mortality, urinary NGAL had the best
discriminatory power, the best Youden index, and the highest overall correctness of prediction.
Conclusions: Our data showed that serum CysC has the best discriminative power for predicting AKI in CCU patients.
However, urinary NGAL and serum IL-18 are associated with short-term mortality in these critically ill patients.
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Introduction
Acute kidney injury (AKI) that develops after admission to
coronary care unit (CCU) is associated with very poor outcomes
[1,2]. Contrast-induced acute kidney injury (CI-AKI) is an
important health issue, as it commonly has a major impact on
outcome [3]. The CI-AKI, defined as a $25% increase in SCr
level, may have an incidence as high as 15% in patients
undergoing coronary angiography [4].
Serum creatinine (SCr), however, is a poor marker of early renal
dysfunction because serum concentration is greatly influenced by
changes in muscle mass and tubular secretion [5,6]. Hence, the
normal reference interval is relatively wide, and SCr alone cannot
precisely indicate disease progression. The numerous non-renal
factors affecting SCr concentration include body weight, race, age,
gender, total body volume, drugs, muscle metabolism and protein
intake. Moreover, SCr increases slowly after onset of AKI. By the
time a SCr change is noted, a critical therapeutic window may
have been missed, particularly in patients with acute tubular
necrosis. A troponin-like biomarker of AKI that is easily measured,
independent of other biological variables, and that provides both
early detection and risk stratification would be a tremendous
advance in clinical medicine. The tools of modern science have
provided promising AKI biomarkers with potentially high
sensitivity and specificity for predicting of AKI and mortality risk
after AKI [7]. The aim of this study was to identify the relationship
between AKI/short-term prognosis and AKI biomarkers in CCU
patients including serum and urinary cystatin C (CysC), neutrophil
gelatinase-associated lipocalin (NGAL) and interleukin-18 (IL-18).
Materials and Methods
Study design and patient population
This investigation was performed in the CCU at a tertiary care
referral center in Taiwan between September 2009 and August
2010. The institutional review board at Chang Gung Memorial
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and written consent to participate in the study. In total, 150 critical
ill patients were enrolled. Exclusion criteria were as follows: unable
to give written informed consent (14 patients), pediatric patient
(ages #18 years) (3 patients); history of end-stage renal failure
(5 patients); duration of hospital stay ,24 h (10 patients).
Readmitted patients were also excluded (6 patients).
Data collection
Daily measurements of urine output (UO) and SCr began on
day 1 of CCU admission and continued for 2 days. Quantification
of CysC, NGAL, and IL-18 was performed in serum and urinary
samples from all patients on CCU admission. Prospectively
collected data were the following: demographic characteristics,
reason for CCU admission, primary diagnosis, routine chemistry
tests, duration of hospitalization, and outcome. To determine the
predictive value of biomarkers at AKI diagnosis, the primary study
outcome was AKI onset. To assess the prognostic utility of
biomarkers, the secondary outcome was 6-month mortality. After
hospital discharge, 6-month follow up examinations were
performed via records review or telephone interview as needed.
Definitions
Acute myocardial infarction (AMI) was defined according to the
2007 Expert Consensus Document of Circulation, European
Heart Journal [8]. Diagnosis of heart failure was based on
Framingham criteria [9]. Sepsis and respiratory failure were
defined according to the American College of Chest Physicians/
Society of Critical Care Medicine (ACCP/SCCM) Consensus
Conference [10]. Illness severity was assessed using Acute
Physiology, Age and Chronic Health Evaluation II (APACHE
II), which was calculated as described elsewhere [11]. Acute
kidney injury was defined as in the Acute Kidney Injury Network
(AKIN) classification system, which requires at least two SCr
values within 48 h [12]. The classification system comprises
individual criteria for SCr levels and UO. A patient can fulfill the
criteria via changes in SCr concentrations, changes in UO, or
both. Baseline SCr concentration used for AKIN classification was
that at the time of CCU admission. The estimated glomerular
filtration rate (eGFR) was estimated using the Chinese Modifica-
tion of Diet in Renal Disease equation [13].
Sampling and quantifying serum and urinary biomarkers
Blood and urinary samples collected in nonheparinized tubes
immediately after CCU admission were centrifuged at 1,500 rpm
for 5 minutes. These samples were then stored at 280uC until
assay. Serum and urinary CysC and NGAL were measured in
duplicate by single ELISA (R&D Systems, Minneapolis, MN,
USA). Serum and urinary IL-18 were measured in duplicate by
single ELISA (Medical and Biologic Laboratories, Nagoya, Japan)
according to manufacturer instructions. Plasma B-type natriuretic
peptide (BNP) level was measured by commercial immunodimetric
assay method. High-sensitive C-reactive protein (hs-CRP) was
measured by autoanalyzer.
Statistical analysis
Continuous variables were summarized by mean and standard
error unless otherwise stated. The primary analysis (the primary
end point) was the comparison between AKI and non-AKI
groups. Kolmogorov-Smirnov test was used to determine the
normal distribution for each variable. Student t-test was used to
compare the means of continuous variables and normally
distributed data; otherwise, Mann-Whitney U test was used.
Categorical data were tested using the Chi-square test or Fisher
exact test. This study utilized the x
2 test for trends to assess
categorical data associated with AKIN classification. Furthermore,
parameters for AKI prediction were assessed using univariate
analysis, and variables that were statistically significant (p,0.05) in
the univariate analysis were included in multivariate analysis by
adopting a multiple logistic regression based on forward
elimination of data. Risk factors for 6-month mortality (the second
end point) were assessed by univariate Cox logistic regression
hazard analysis, and statistically significant (p,0.05) variables
identified by univariate hazard analysis were included in the
multivariate analysis by applying multiple logistic forward Cox
regression analysis to obtain independent predictors of 6-month
survival.
Hosmer-Lemeshow goodness-of-fit test was used for calibration
when evaluating the number of observed and predicted deaths in
risk groups for the entire range of death probabilities. Discrim-
ination was assessed using the area under a receiver operating
characteristic curve (AUROC), which was compared by a
nonparametric approach [14]. The AUROC analysis calculated
cutoff values, sensitivity, specificity, and overall correctness.
Finally, cutoff points were calculated by acquiring the best
Youden index [15]. The index is defined as sensitivity+specificity
21, where sensitivity and specificity are calculated as proportions.
Youden index has minimum and maximum values of 21 and +1,
respectively, with a value of +1 representing the optimal value for
an algorithm. Cumulative survival curves as a function of time
were generated by Kaplan-Meier approach and compared by log
rank test. All statistical tests were two-tailed; a value of p,0.05 was
considered statistically significant.
Results
Subject characteristics
Between September 2009 and August 2010, 150 CCU patients
with AMI, congestive heart failure, respiratory failure, or
arrhythmias were enrolled. Median subject age was 69-year-old;
one hundred and thirteen (75.3%) were male, and thirty-seven
(24.7%) were female. The causes of CCU admission were AMI in
120 (80%) patients, congestive heart failure in 21 (14%),
respiratory failure in five (3.3%), tachyarrhythmia or bradyar-
rhythmia in three (2%), and AKI in one patient (0.7%), who was
managed conservatively with intravenous inotropic agents plus
diuretics and hemodynamic monitoring. No patient required
hemodialysis on day 1 of CCU admission.
AKI and biomarkers
Overall, 28.7% (43/150) patients had AKI (AKIN SCr criteria
only: 25 patients, UO criteria only: 3 patients, and SCr plus UO
criteria: 15 patients). In AKIN classification, 6-month mortality
was 3.7% (4/107) for stage-0, 23.5% (4/17) for stage-1, 18.2%
(2/11) for stage-2, and 46.7% (7/15) for stage-3 patients (x2 for
trend, p,0.001). Table 1 lists that the AKI patients had a
significantly high incidence of sepsis, older age as well as high
values for APACHE II, blood sugar, baseline SCr concentration,
BNP, hs-CRP, CysC, IL-18, and serum and urinary NGAL. They
also tended to have low ejection fraction, hemoglobulin (Hb) and
serum albumin on CCU day 1 and elevated 6-month mortality
(Fig. 1).
To assess calibration, Table 2 shows the goodness-of-fit indices
as measured by the Hosmer-Lemeshow chi-square analysis of
predicted AKI risk and the predictive accuracy of the APACHE
II, serum and urinary CysC, NGAL and IL-18 for these patients.
Table 2 also compares the discriminatory power of APACHE II
AKI Biomarkers for Patients in CCU
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serum CysC was the best AKI predictor in the overall CCU
population (AUROC 0.89560.031, p,0.001). There were no
significant changes in AUROCs for urinary NGAL, IL-18 or
CysC after normalizing for urine creatinine (Ucr, data not shown).
Univariate analysis identified 15 of the 30 variables (Table 1) as
AKI prediction valuable (Table 3). Multivariate analysis identified
the following variables as of independent predicting AKI
significance: serum NGAL and CysC (Table 3). Regression
coefficients of these variables were utilized to calculate a logit of
death for each patient as follows:
The logarithm of the odds of AKI~
{6:454z0:013|serum NGALz0:001|serum CysC:
Short-term mortality and AKI biomarkers
The overall 6-month mortality rate was 11.3% (17/150). Table 4
lists patient demographic data and clinical characteristics for both
6-month survivors and non-survivors. Of thirty variables (Table 4),
univariate Cox logistic regression hazard analysis identified 15
with prognostic value for 6-month mortality (Table 5). Multiple
Cox logistic regression hazard analysis revealed that APACHE II,
serum sodium, urinary NGAL and serum IL-18 on CCU
admission day one were independent risk factors for 6-month
mortality (Table 5).
Table 2 shows the goodness-of-fit, as measured by the Hosmer-
Lemeshow chi-square statistic of predicted 6-month mortality risk,
for the predictive accuracy of the APACHE II and AKI
biomarkers. Table 2 also compares discriminatory power for
APACHE II, serum and urinary CysC, NGAL, and IL-18. The
AUROC analysis verified that urinary NGAL had the best
discriminatory power for predicting 180-day mortality. To assess
the predictive value of selected cut-offs for predicting 6-month
mortality, the sensitivity, specificity and overall correctness of
prediction were determined. Table 6 summarizes the data
calculated using the cutoff point providing the best Youden index.
The urinary NGAL had the best Youden index and highest overall
correctness of prediction.
Discussion
This study confirmed that serum CysC, IL-18, NGAL, and
urinary NGAL on CCU admission day one were prognostically
significant biomarkers of AKI. This study also confirmed that
APACHE II, serum sodium, urinary NGAL and serum IL-18 on
CCU admission day 1 were strongly correlated with 180-day
mortality.
McCullough and colleagues reported that renal risk stratifica-
tion can identify groups with high rates of CCU death and poor
long-term survival. This risk is only partially explained by
comorbidities, including diabetes, age and congestive heart failure
(CHF) [16]. This investigation found that 21 CHF patients as the
Figure 1. Cumulative survival rate for 150 critically ill patients based on with/without acute kidney injury (AKI) at 48-hour after
coronary care unit admission.
doi:10.1371/journal.pone.0032328.g001
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rate (28.6%). Increased SCr, hyperbilirubinemia, and dilutional
hyponatremia are observed in severe CHF cases. Dilutional
hyponatremia occurs in patients with decreased free-water
clearance driven by nonosmotic secretion of vasopressin secondary
to circulatory dysfunction and effective hypovolemia [17]. Linear
correlation analysis revealed a converse correlation between serum
sodium concentration and SCr levels on the first day of CCU
admission (r=20.237, p=0.004) in this study.
Normally, CysC, which is a 13-kDa protein, is filtered freely and
completely reabsorbed and catabolized within the proximal
tubule. Some limitations of the SCr level, including the effects of
gender, body muscle mass, and diet, did not significantly influence
serum CysC levels. It is a relatively stable protein in serum that
shows promise as a convenient measure of glomerular filtration
rate (GFR) [18]. Moreover, although CysC is normally not
detected in urine, elevated urine CysC levels may indicate tubular
epithelial damage, and has been proposed as an additional urine
biomarker for AKI [19]. Unlike other potential AKI biomarkers,
CysC is not affected by storage conditions or interfering substances
and does not increase with urinary tract infection or other chronic
non-kidney disease states, such as malignancy [20]. Because it is a
marker of glomerular filtration, the protein is valuable for
identifying established AKI. As a predictor of dialysis requirements
or in-hospital death in AKI, serum CysC level is as accurate as
SCr level, serum urea nitrogen level, and urine output [21].
Furthermore, Heise and colleagues reported that neither urinary
CysC concentrations nor their product with the creatinine ratios
showed any significant differences between the AKI and non-AKI
patient groups [22]. In this study, serum but not urinary CysC
level had better discriminatory power, Youden index, and overall
accuracy in predicting AKI compared to other biomarkers.
Urinary NGAL concentrations were significantly higher in
patients with AKI and accurately discriminated between both
groups with satisfactory sensitivity and specificity. However, the
variability of urinary NGAL within both groups was much higher
Table 1. Patient demographic data and clinical characteristics on the first of CCU admission according to with/without AKI.
All Patients
(n=150)
Without AKI
(n=107)
With AKI
(n=43) p-value
Age (years) 66616 3 617 3 62 ,0.001
Gender, Male (%) 113 (75) 83 (78) 30 (70) NS (0.316)
Diabetes mellitus, n (%) 92 (61) 61 (57) 31 (72) NS (0.086)
Hypertension, n (%) 110 (73) 77 (72) 33 (77) NS (0.549)
Sepsis, n (%) 30 (20) 11 (10) 19 (44) ,0.001
Contrast medium exposure, n (%) 114 (76) 84 (79) 30 (70) NS (0.257)
eGFR less than 60 min/ml, n (%) 37 (25) 20 (19) 17 (40) 0.007
Vasoactive/inotropic agents, n (%) 30 (20) 19 (18) 11 (26) NS (0.279)
Mechanical ventilation, n (%) 27 (18) 12 (11) 15 (35) 0.001
History of CAD, n (%) 110 (73) 82 (77) 28 (65) NS (0.149)
Mean arterial pressure (mmHg) 80617 9 628 1 63 NS (0.453)
AST (units/L) 80613 83618 72610 NS (0.711)
Blood sugar (mg/dL) 169671 5 8 671 9 6 613 NS (0.054)
Serum Creatinine (mg/dL) 1.3360.07 1.1960.06 1.6860.27 0.013
Total Bilirubin (mg/dL) 0.660.0 0.660.0 0.560.0 0.042
Albumin (g/L) 3.760.0 3.960.0 3.460.1 ,0.001
Hemoglobin (g/dL) 12.760.2 13.260.2 11.460.4 ,0.001
Leukocytes (610
3/mL) 10.160.3 10.060.4 10.560.6 NS (0.469)
Serum Sodium (mmol/L) 139601 3 9 601 3 9 61 NS (0.958)
hs-CRP (mg/L) 42653 4 666 2 610 0.002
Troponin I (ng/mL) 6.861.1 4.660.9 12.963.4 0.022
BNP (pg/mL) 690673 458665 12686169 ,0.001
Ejection fraction (%) 51615 3 614 5 630 . 0 1 1
APACHE II (points) 10618 611 4 61 ,0.001
Serum NGAL (ng/mL) 149611 110682 5 9 629 ,0.001
Urine NGAL (ng/mL) 74617 22642 2 1 660 0.002
Serum IL-18 (pg/mL) 450621 397625 582631 ,0.001
Urine IL-18 (pg/mL) 71656 0 649 8 616 0.026
Serum CysC (mg/L) 2.160.2 1.260.1 4.160.7 ,0.001
Urine CysC (mg/L) 2.961.3 1.360.4 7.064.4 NS (0.204)
AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; AST, aspartate aminotransferase; BNP, B-type natriuretic peptide; CAD, coronary
artery disease; CCU, coronary care unit; CysC, cystatin C; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C reactive protein; IL-18, interleukin-18; NGAL:
neutrophil gelatinase-associated lipocalin; NS, not significant.
doi:10.1371/journal.pone.0032328.t001
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AKI and 6-month mortality.
Calibration Discrimination
goodness-of-fit (x
2)d f p AUROC 6 SE 95% CI p
For AKI prediction
Serum NGAL 10.591 8 0.226 0.82860.036 0.758–0.898 ,0.001
Urine NGAL 13.602 8 0.093 0.79660.044 0.710–0.882 ,0.001
Serum IL-18 23.873 8 0.002 0.77360.038 0.698–0.847 ,0.001
Urine IL-18 13.008 8 0.112 0.62160.060* 0.504–0.738 0.032
Serum CysC 9.491 8 0.303 0.89560.031 0.834–0.956 ,0.001
Urine CysC 8.793 8 0.360 0.63360.061* 0.514–0.751 0.019
APACHE II 10.717 8 0.151 0.75760.039 0.690–0.844 ,0.001
For 6-month mortality prediction
Serum NGAL 12.185 8 0.143 0.83660.049 0.740–0.933 ,0.001
Urine NGAL 10.701 8 0.219 0.88660.036 0.815–0.957 ,0.001
Serum IL-18 13.829 8 0.086 0.84160.055 0.734–0.948 ,0.001
Urine IL-18 11.702 8 0.165 0.75560.077 0.604–0.906 0.001
Serum CysC 5.439 8 0.710 0.86160.044 0.774–0.948 ,0.001
Urine CysC 5.577 8 0.695 0.56760.089{ 0.391–0.742 0.375
APACHE II 4.347 8 0.825 0.85860.061 0.764–0.952 ,0.001
AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; AUROC, areas under the receiver operating characteristic curve; CI, confidence
intervals; CysC, cystatin C; df, degree of freedom; IL-18, interleukin-18; NGAL: neutrophil gelatinase-associated lipocalin; SE, standard error.
*, p,0.05 vs. Serum NGAL and CysC;
{, p,0.05 vs. APACHE II, Urine NGAL and Serum CysC.
doi:10.1371/journal.pone.0032328.t002
Table 3. Logistic regression analysis for AKI, according to baseline prognostic factors on the first day of CCU admission.
Parameter
Beta
Coefficient Standard error
Odds ratio
(95%CI) p
Univariate logistic regression
Age 0.085 0.020 1.089 (1.048–1.132) ,0.001
Sepsis 1.933 0.442 6.909 (2.904–16.440) ,0.001
eGFR less than 60 min/ml 1.045 0.398 2.844 (1.303–6.211) 0.009
Mechanical ventilation 1.445 0.443 4.241 (1.780–10.105) 0.001
Serum Creatinine, CCU first day 0.548 0.196 1.729 (1.177–2.540) 0.005
Albumin 22.382 0.485 0.092 (0.036–0.239) ,0.001
Hemoglobin 20.345 0.087 0.708 (0.597–0.840) ,0.001
BNP 0.001 0.000 1.001 (1.001–1.002) ,0.001
Ejection fraction 20.034 0.012 0.967 (0.945–0.989) 0.004
APACHE II 0.158 0.036 1.171 (1.092–1.256) ,0.001
Serum NGAL 0.009 0.002 1.009 (1.005–1.013) ,0.001
Urine NGAL 0.012 0.004 1.012 (1.004–1.020) 0.004
Serum IL-18 0.003 0.001 1.003 (1.001–1.004) ,0.001
Urine IL-18 0.013 0.005 1.013 (1.004–1.022) 0.007
Serum CysC 0.002 0.000 1.002 (1.001–1.002) ,0.001
Multivariate logistic regression
Serum NGAL 0.013 0.006 1.013 (1.001–1.025) 0.028
Serum CysC 0.001 0.001 1.001 (1.000–1.003) 0.036
constant 26.454 1.184 - -
AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; BNP, B-type natriuretic peptide; CCU, coronary care unit; CI, confidence intervals;
CysC, cystatin C; eGFR, estimated glomerular filtration rate; IL-18, interleukin-18; NGAL: neutrophil gelatinase-associated lipocalin.
doi:10.1371/journal.pone.0032328.t003
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[23], in which the authors noted several rare comorbidities in
young patients, which may increase NGAL excretion independent
of kidney injury. Such conditions include chronic heart failure
[24], atherosclerosis [25], vascular injury [26], the need for dialysis
within the first week of kidney transplantation [27] and
neutrophilic inflammation [28]. Despite these confounding factors,
the present study shows that urinary NGAL accurately indicates
AKI and short-term mortality in adult patients with a broad
spectrum of comorbidities.
A large study of healthy, middle-aged European men also
showed that serum IL-18 concentration is an independent
predictor of coronary events [29]. Additionally, variation within
the IL-18 gene is known to influence circulating concentrations of
IL-18 and clinical outcome in patients with coronary heart disease
(CHD) [30]. The exact influence of IL-18 on CHD risk remains
unclear. The IL-18 shares similar downstream signaling pathways
with several other cytokines (e.g.,interaction with MyD88 [31] and
nuclear translocation of NF-kB [32]), but this may not be true for
all cell types [33]. Animal studies indicate that both IL-6 and IL-1
induce fever [34] whereas IL-18 does not [35], which suggests
substantial differences in site and mode of action between these
cytokines. Also, IL-18 reportedly predicts CHD events indepen-
dent of CRP [29], which further supports this hypothesis.
Therefore, if IL-18 participates in an alternative inflammatory
pathway in CHD, knowledge of important genetic effects may
improve risk prediction beyond that of other inflammatory
mediators [36]. Moreover, 6-month mortality rates differed
significantly according to the best Youden index below and above
the cut-off value of 442 pg/mL serum IL-18 (1.1% vs. 27.6%,
p,0.001) in this investigation.
A recently published article reported the incidence, cost, and
outcome of severe sepsis in the United States. Analysis of a large
sample from major centers identified an incidence of severe sepsis
as 3 cases per 1,000 people, and 2.26 cases per 100 hospital
discharges. Out of these cases, 51.1% were admitted to intensive
care units; an additional 17.3% were cared for in intermediate
care units or CCUs [37]. In this investigation, the incidence of
CCU patients with sepsis was roughly 20% (30/150) (Table 1).
This high sepsis incidence can be attributed to the cause of CCU
admission; that is, a high proportion of patients had congestive
heart failure (14%) and respiratory failure (3.3%). Furthermore,
the overall CI-AKI in this study was 26.3% (30/114), which is
high compared to that in other studies [4]. This high AKI
incidence may be attributable to inclusion of 37 patients with an
eGFR ,60 min/ml and 30 septic patients; both of which are
positively associated with AKI.
Despite the promising results obtained in this study, several
important limitations are noted. First, this study was conducted at
just one institution. Therefore, the results may not be directly
extrapolated to other patient populations. Second, predictions
vary among individuals; that is, a prediction is only an
approximate indicator of mortality risk in specific subjects. Of all
CCU patients in this cohort, most had ischemic AKI. Notably,
AKI is often multifactorial, and experimental results require
validation by a relatively larger randomized prospective trial.
Third, the AKI definition was based on elevated SCr concentra-
tions and/or oliguria, which raises the problem of using a flawed
‘‘gold standard’’ to analyze the performance of novel biomarkers
[38]. This is an important limitation of this study. Besides, the use
of the first measured SCr at the ICU admission can actually
decrease the diagnosis of AKI, since some patients will already
have AKI at the time of ICU admission. On the other hand, those
patients could have higher levels of biomarkers, interfering with
the performance of these markers to predict and prognosis AKI.
Fourth, the number of mechanically ventilated patients (n=27),
patients with eGFR less than 60 min/ml (n=37) and one pre-
existing AKI patient as well as outcome events was insufficient to
determine independent risk factors for AKI and 6-month mortality
by using multivariate techniques. Recent evidence suggests that
the predictive ability of biomarkers for AKI is reduced in patients
with chronic kidney disease [39]. Finally, sequential measurement
of these AKI biomarkers (e.g., daily, weekly) or other AKI
biomarkers (e.g., kidney injury molecule-1, liver fatty acid-binding
proteins) may reflect the dynamic aspects of clinical diseases and
thus provide superior information on mortality risk.
Table 4. Patient demographic data and clinical characteristics
on the first of CCU admission according to 6-month mortality.
Survivors
(n=133)
Non-survivors
(n=17) p-value
Age (years) 64617 5 62 ,0.001
Gender, Male (%) 103 (77) 10 (59) NS (0.094)
Diabetes mellitus, n (%) 84 (63) 8 (47) NS (0.199)
Hypertension, n (%) 95 (71) 15 (88) NS (0.140)
Sepsis, n (%) 22 (17) 8 (47) 0.003
Contrast medium exposure,
n (%)
104 (78) 10 (59) NS (0.078)
eGFR less than 60 min/ml,
n (%)
27 (20) 10 (59) 0.001
Vasoactive/inotropic agents,
n (%)
28 (21) 2 (12) NS (0.367)
Mechanical ventilation, n (%)18 (14) 9 (53) ,0.001
History of CAD, n (%) 101 (76) 9 (53) 0.043
Mean arterial pressure
(mmHg)
79628 4 65 NS (0.307)
AST (units/L) 76614 106621 NS (0.479)
Blood sugar (mg/dL) 171671 5 8 69 NS (0.314)
Serum Creatinine (mg/dL) 1.256 0.07 1.9760.30 0.031
Total Bilirubin (mg/dL) 0.660.0 0.760.1 NS (0.297)
Albumin (g/L) 3.860.0 3.260.1 ,0.001
Hemoglobin (g/dL) 13.060.2 10.660.4 ,0.001
Leukocytes (610
3/mL) 9.860.3 12.561.1 0.007
Serum Sodium (mmol/L) 139601 3 6 61 0.005
hs-CRP (mg/L) 32641 0 4 630 0.030
Troponin I (ng/mL) 5.561.0 17.165.8 NS (0.068)
BNP (pg/mL) 560667 17146281 0.001
Ejection fraction (%) 52614 2 65 NS (0.073)
APACHE II (points) 9601 9 62 ,0.001
Serum NGAL (ng/mL) 126693 2 0 651 0.002
Urine NGAL (ng/mL) 36683 5 1 6114 0.014
Serum IL-18 (pg/mL) 411618 747691 0.002
Urine IL-18 (pg/mL) 62631 4 1 638 NS (0.055)
Serum CysC (mg/L) 1.660.1 5.661.5 0.021
Urine CystC (mg/L) 1.260.4 16.4610.6 NS (0.173)
APACHE, Acute Physiology and Chronic Health Evaluation; AST, aspartate
aminotransferase; BNP, B-type natriuretic peptide; CAD, coronary artery disease;
CCU, coronary care unit; CysC, cystatin C; eGFR, estimated glomerular filtration
rate; hs-CRP, high-sensitivity C reactive protein; IL-18, interleukin-18; NGAL:
neutrophil gelatinase-associated lipocalin; NS, not significant.
doi:10.1371/journal.pone.0032328.t004
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admission.
Parameter
Beta
Coefficient Standard error
Hazard ratios
(95%CI) p
Univariate hazard analysis
Age (years) 0.072 0.025 1.075 (1.023–1.129) 0.004
Mechanical ventilation 1.778 13.355 5.919 (2.281–15.362) ,0.001
Sepsis 1.393 0.486 4.026 (1.553–10.441) 0.004
eGFR less than 60 min/ml 1.724 0.538 5.608 (1.954–16.905) 0.001
Serum Creatinine, CCU first day 0.519 0.178 1.680 (1.186–2.382) 0.004
Albumin 21.933 0.450 0.145 (0.060–0.350) ,0.001
Hemoglobin 20.401 0.105 0.669 (0.545–0.823) ,0.001
Serum Sodium 20.199 0.064 0.819 (0.723–0.928) 0.002
hs-CRP 0.011 0.003 1.011 (1.006–1.016) ,0.001
BNP 0.001 0.000 1.001 (1.000–1.001) ,0.001
APACE II 0.160 0.027 1.173 (1.113–1.237) ,0.001
Serum NGAL 0.007 0.001 1.007 (1.005–1.010) ,0.001
Urine NGAL 0.003 0.000 1.003 (1.002–1.004) ,0.001
Serum IL-18 0.003 0.001 1.003 (1.002–1.004) ,0.001
Urine IL-18 0.005 0.001 1.005 (1.003–1.007) ,0.001
Multivariate hazard analysis
Urine NGAL 0.003 0.001 1.003 (1.001–1.004) ,0.001
Serum IL-18 0.005 0.001 1.005 (1.003–1.006) ,0.001
APACE II 0.129 0.036 1.138 (1.061–1.221) ,0.001
Serum Sodium 20.352 0.103 0.703 (0.575–0.860) 0.001
APACHE, Acute Physiology and Chronic Health Evaluation; BNP, B-type natriuretic peptide; CCU, coronary care unit; CI, confidence intervals; hs-CRP, high-sensitivity C
reactive protein; IL-18, interleukin-18; NGAL: neutrophil gelatinase-associated lipocalin.
doi:10.1371/journal.pone.0032328.t005
Table 6. Predictions of the biomarkers and APACHE II on the first of CCU admission in predicting AKI and 6-month mortality.
Predictive
Factors
Cutoff
Point Youden Index Sensitivity (%) Specificity (%) Overall Correctness (%)
For AKI prediction
Serum NGAL 110* 0.61 92 69 81
Urine NGAL 33* 0.50 66 84 75
Serum IL-18 374* 0.62 97 65 81
Urine IL-18 70* 0.34 50 84 67
Serum CysC 1.8* 0.68 77 91 84
Urine CysC 0.2* 0.30 46 84 65
APACHE II 7* 0.39 93 46 70
For 6-month mortality prediction
Serum NGAL 135* 0.64 88 76 82
Urine NGAL 33* 0.68 88 80 84
Serum IL-18 442* 0.65 94 71 83
Urine IL-18 77* 0.43 67 76 72
Serum CysC 2.1* 0.67 77 90 84
Urine CysC 0.2* 0.27 47 80 64
APACHE II 14* 0.64 77 87 82
AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; CysC, cystatin C; IL-18, interleukin-18; NGAL: neutrophil gelatinase-associated
lipocalin.
*Value giving the best Youden index (sensitivity+specificity 21).
doi:10.1371/journal.pone.0032328.t006
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e32328The analytical data demonstrated the good discriminative
power of serum CysC and NGAL levels for predicting AKI in
these critically ill patients. This study also indicated that APACHE
II, serum sodium concentrations, urinary NGAL and serum IL-18
on day 1 of CCU admission are independent predictors of 180-day
mortality. The AKI biomarkers panel is useful when timing the
initial insult and predicting AKI duration, severity and clinical
outcomes. However, because of the relatively small sample size,
the predictive accuracies of serum CysC, NGAL, and IL-18 levels
and urinary NGAL of CCU population require further external
validation.
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